High-throughput screening is one of the most powerful and unbiased approaches for identifying new drug leads. Up to millions of small molecules are tested in a biochemical assay to reveal compounds that inhibit enzyme activity. Most assays rely on labels that generate high rates of false positive results. Following any screen, it is therefore critical to eliminate these artifacts and focus efforts on the most promising hits to move towards a hit-to-lead program.
Learn how SAMDI Tech designed an assay suitable for screening and supported hit-to-lead optimization efforts including IC50 analysis and REDOX triage.